Efficacy assessment of pemetrexed treatment of an NSCLC case with brain metastasis
- Authors:
- Jing Liang
- Xiaolin Liu
- Beibei Yin
- Hairong Liu
- Junjuan Xiao
- Yan Li
View Affiliations
Affiliations: Department of Oncology, Qianfoshan Hospital, Shandong University, Jinan, Shandong 250014, P.R. China
- Published online on: August 30, 2012 https://doi.org/10.3892/ol.2012.888
-
Pages:
1119-1121
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Non-small cell lung cancers (NSCLCs) are among the most common malignancies. Although pemetrexed is often used clinically to cure cancers, its efficacy in NSCLC patients with progressive brain metastases remains unclear. Here, we report a successful NSCLC (adenocarcinoma) case treated with pemetrexed. The detected tumors were treated with 900 mg of pemetrexed disodium (500 mg/m2) was administered to the patient on day 1, and 40 mg of cisplatin (25mg/m2) was administered on days 1-3, at the interval of 3 weeks. After two cycles of chemotherapy, the brain metastases were reduced. The lesion in the lung was reduced as determined by chest CT-scan. Our results suggest that pemetrexed is an effective therapy for patients with NSCLC and progressive brain metastases.
View References
|
1.
|
V AdamoT FranchinaB AdamoG ScandurraA
ScimoneBrain metastases in patients with non-small cell lung
cancer: focus on the role of chemotherapyAnn
Oncol1711731175200610.1093/annonc/mdj93016608991
|
|
2.
|
T KawabeJH PhiM YamamotoTreatment of brain
metastasis from lung cancerProg Neurol
Surg25148155201210.1159/00033118822236676
|
|
3.
|
P MulvennaR BartonP WilsonSurvival of
patients with non-small cell lung cancer and brain metastasesClin
Oncol (R Coll
Radiol)23375376201110.1016/j.clon.2011.01.50821392952
|
|
4.
|
C ShihVJ ChenLS GossettSB GatesWC
MacKellarLL HabeckLY231514, a pirrolo [2,3-d] pyrimidine-based
antifolate that inhibits multiple folate-requiring enzymesCancer
Res57111611231997
|
|
5.
|
F BarlesiR GervaisH LenaJ HureauxH BerardD
PaillotinPemetrexed and cisplatin as first-line chemotherapy for
advanced non-small-cell lung cancer (NSCLC) with asymptomatic
inoperable brain metastases: a multicenter phase II trial (GFPC
07-01)Ann Oncol2224662470201110.1093/annonc/mdr00321321089
|
|
6.
|
RM SchultzVJ ChenJR BewleyEF RobertsC
ShihJA DempseyBiological activity of the multitargeted antifolate,
MTA (LY231514), in human cell lines with different resistance
mechanisms to antifolate drugsSemin Oncol266873199910598558
|
|
7.
|
H DaiY ChenWF ElmquistDistribution of the
novel antifolate pemetrexed to the brainJ Pharmacol Exp
Ther315222229200510.1124/jpet.105.09004315987831
|
|
8.
|
W OrtuzarN HannaE PennellaG PengC LangerM
MonbergG ScagliottiBrain metastases as the primary site of relapse
in two randomized phase III pemetrexed trials in advanced
non-small-cell lung cancerClin Lung
Cancer132430201210.1016/j.cllc.2011.05.00721831719
|
|
9.
|
W SchuetteH TeschH BüttnerT KrauseV
SoldatenkovaC StoffregenSecond-line treatment of stage III/IV
non-small-cell lung cancer (NSCLC) with pemetrexed in routine
clinical practice: Evaluation of performance status and
health-related quality of lifeBMC
Cancer1214201210.1186/1471-2407-12-1422244076
|
|
10.
|
CG AzzoliS TeminT AliffS Baker JrJ
BrahmerDH JohnsonJL Laskin2011 Focused update of 2009 American
Society of Clinical Oncology clinical practice guideline update on
chemotherapy for stage IV non-small-cell lung cancerJ Clin
Oncol2938253831201110.1200/JCO.2010.34.277421900105
|
|
11.
|
D GalettaS PiscontiS CinieriGL PappagalloV
GebbiaN BorsellinoInduction pemetrexed and cisplatin followed by
maintenance pemetrexed versus carboplatin plus paclitaxel plus
bevacizumab followed by maintenance bevacizumab: a quality of
life-oriented randomized phase III study in patients with advanced
non-squamous non-small-cell lung cancer (ERACLE)Clin Lung
Cancer124024062011
|
|
12.
|
A SekineT KatoE HagiwaraT ShinoharaT
KomagataT IwasawaMetastatic brain tumors from non-small cell lung
cancer with EGFR mutations: Distinguishing influence of exon 19
deletion on radiographic featuresLung
Cancer776469201210.1016/j.lungcan.2011.12.01722335887
|
|
13.
|
M Jamal-HanjaniJ SpicerEpidermal growth
factor receptor tyrosine kinase inhibitors in the treatment of
epidermal growth factor receptor-mutant non-small cell lung cancer
metastatic to the brainClin Cancer
Res18938944201210.1158/1078-0432.CCR-11-252922167408
|
|
14.
|
GA PesceD KlingbielK RibiA ZouhairR von
MoosM SchlaeppiOutcome, quality of life and cognitive function of
patients with brain metastases from non-small cell lung cancer
treated with whole brain radiotherapy combined with gefitinib or
temozolomide. A randomised phase II trial of the Swiss Group for
Clinical Cancer Research (SAKK 70/03)Eur J Cancer483773842012
|
|
15.
|
S HeonBY YeapGJ BrittDevelopment of
central nervous system metastases in patients with advanced
non-small cell lung cancer and somatic EGFR mutations treated with
gefitinib or erlotinibClin Cancer
Res1658735882201010.1158/1078-0432.CCR-10-158821030498
|
|
16.
|
A BearzI GarassinoM TiseoActivity of
Pemetrexed on brain metastases from non-small cell lung cancerLung
Cancer68264268201010.1016/j.lungcan.2009.06.01819632738
|
